Ruzasvir + Bemnifosbuvir Sulfate is a small molecule commercialized by Atea Pharmaceuticals, with a leading Phase II program in Hepatitis C. According to Globaldata, it is involved in 12 clinical trials, of which 8 were completed, 1 is ongoing, 1 is planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Ruzasvir + Bemnifosbuvir Sulfate’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for Ruzasvir + Bemnifosbuvir Sulfate is expected to reach an annual total of $43 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Ruzasvir + Bemnifosbuvir Sulfate Overview

Ruzasvir is under development for the treatment of hepatitis C infection. The drug candidate is administered orally and targets NS5A antigen.

Atea Pharmaceuticals Overview

Atea Pharmaceuticals is a clinical-stage biopharmaceutical company. It develops, discovers and commercializes therapies for treatment of life-threatening viral infections. The company product pipeline includes bemnifosbuvir (AT-527) for the treatment of COVID-19, the disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and bemnifosbuvir in combination with ruzasvir for the treatment of hepatitis C virus (HCV). Atea Pharmaceuticals carries out purine nucleotide prodrug platform to transform treatment of severe viral diseases. It also includes in development of orally-available antiviral agents for serious viral infections. Atea Pharmaceuticals is headquartered in Boston, Massachusetts, the US.
The operating loss of the company was US$164.2 million in FY2023, compared to an operating loss of US$130.7 million in FY2022. The net loss of the company was US$136 million in FY2023, compared to a net loss of US$115.9 million in FY2022.

For a complete picture of Ruzasvir + Bemnifosbuvir Sulfate’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.